Alumis, Inc. (ALMS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.10-2.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALMS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete and submit the New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
Stated as a priority in 3 of last 3 quarters. Management consistently reiterated the goal to submit the NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. Financial results show ongoing R&D expenses of $85.3M in 2026-Q2 and $81.5M in 2026-Q1 supporting clinical activities. The trajectory is delivering with no indication of delay.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.”
“Plans to submit NDA in 4Q 2026 remain on track.”
“We remain on track for our NDA submission in the fourth quarter of this year.”
Maintain sufficient cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures into the fourth quarter of 2027.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities totaled approximately $502.3M at 2026-Q2, down from $569.5M at 2026-Q1, supporting funding into Q4 2027 as planned. The trajectory shows a moderate cash decline but remains consistent with management's funding guidance.
“Existing cash, cash equivalents and marketable securities as of June 30, 2026 expected to fund operating expenses and capital expenditure requirements into Q4 2027.”
“Existing cash, cash equivalents and marketable securities as of March 31, 2026 expected to fund operating expenses and capital expenditure requirements into Q4 2027.”
“Existing cash, cash equivalents and marketable securities as of December 31, 2025, plus net proceeds of $324.4 million from public offering, expected to fund operations.”
Progress clinical development with anticipated Phase 2b topline data for SLE in Q3 2026 and long-term data for psoriasis in 2H 2026.
Stated as a priority in 3 of last 3 quarters. The Phase 2b LUMUS trial topline data for SLE was anticipated in Q3 2026 but the trial did not meet primary endpoints overall, though a subgroup showed robust responses. ONWARD3 long-term psoriasis data is expected in 2H 2026. The trajectory shows mixed progress with a clear path forward for SLE development.
“Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026.”
“ONWARD3 long-term data and Phase 2, two-year safety data for psoriasis expected in 2H 2026.”
“Potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter.”
Start a Phase 2 biomarker clinical trial for A-005, a CNS-penetrant TYK2 inhibitor, in Parkinson’s disease patients in the first half of 2027.
Stated as a priority in 2 of last 3 quarters. Management plans to initiate the Phase 2 biomarker trial for A-005 in Parkinson’s disease in 1H 2027. No financial or clinical milestone has yet been reported, indicating early-stage progress consistent with stated plans.
“Plans to initiate a Phase 2 biomarker trial for A-005 in Parkinson’s disease in the first half of 2027.”
“Advancing A-005 into a Phase 2 biomarker trial in Parkinson’s disease patients planned for 1H 2027.”
Complete strategic review and explore alternatives for the lonigutamab asset.
Stated as a priority in 2 of last 3 quarters. Management has completed a strategic review and is exploring alternatives for lonigutamab. No financial impact or milestone reported yet, indicating ongoing evaluation consistent with prior statements.
“Completed strategic review of the lonigutamab program and decided to explore strategic alternatives.”
“Completed strategic review of the lonigutamab program and exploring strategic alternatives.”
Over the trailing year it converted 0.86x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
11 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.